Times of IndiaLean R·
Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer. Notably, Orca-T significantly minimizes the chances of graft-versus-host disease post-stem cell transplants, offering reduced chemotherapy requirements and lower side effects. Future studies are anticipated to investigate i…
Read at Times of India →
